Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Go back to Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval| Goss & De Leeuw Mach Co (NASDAQ: GOSS) | Delayed: 11.28 +0.55 (5.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.73 | 52 Week High | $0.00 | |||
| Open | $11.60 | 52 Week Low | $0.00 | |||
| Day High | $11.94 | P/E | N/A | |||
| Day Low | $10.91 | EPS | $0.00 | |||
| Volume | 258,915 | |||||
